Sihuan Pharmaceutical (00460) rose more than 5%. As of press release, it rose 5.36% to HK$0.59, with a turnover of HK$3,532 million.
The Zhitong Finance App learned that Sihuan Pharmaceutical (00460) rose by more than 5%. As of press release, it had risen 5.36% to HK$0.59, with a turnover of HK$3,532 million.
According to the news, Sihuan Pharmaceutical recently announced that the sodium-glucose transporter 2 inhibitor (SGLT-2 inhibitor) developed by Huisheng Biotech, a non-wholly-owned subsidiary of the group, and proline gagliflozin tablets (trade name: Huiyoujing, “gagliflozin”) have been approved for marketing by the State Drug Administration to treat type 2 diabetes. According to reports, this is the second self-developed SGLT-2 inhibitor innovative drug approved for marketing in China, marking that Huisheng Biotech has made breakthrough progress in developing innovative drugs in the field of diabetes treatment.
Clinical phase III study data showed that gagliflozin not only had significant hypoglycemic efficacy (the decrease in glycated hemoglobin was up to 1.4% from the baseline); it also had multiple benefits such as lowering blood pressure, weight loss, and improving blood lipids. The risk of hypoglycemia was low, and overall safety was good. In a horizontal comparison with the phase III clinical data results of similar SGLT-2 inhibitor products already on the market, gagliflozin showed similar or even better results.